An open label neoadjuvant study to assess the effect of Avastin on tumor response in patients with inflammatory or locally advanced breast cancer

Trial Profile

An open label neoadjuvant study to assess the effect of Avastin on tumor response in patients with inflammatory or locally advanced breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 May 2013 Planned end date changed from 1 Dec 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 15 Mar 2011 Planned end date changed from 1 Apr 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top